Seroquel XR Dosage

Generic name: QUETIAPINE FUMARATE 200mg
Dosage form: tablet, extended release
Drug class: Atypical antipsychotics

Medically reviewed by Drugs.com. Last updated on Jan 17, 2024.

Important Administration Instructions

SEROQUEL XR tablets should be swallowed whole and not split, chewed, or crushed.

It is recommended that SEROQUEL XR be taken without food or with a light meal (approximately 300 calories) [see Clinical Pharmacology (12.3)].

SEROQUEL XR should be administered once daily, preferably in the evening.

Recommended Dosing

The recommended initial dose, titration, dose range and maximum SEROQUEL XR dose for each approved indication is displayed in Table 1 below. After initial dosing, adjustments can be made upwards or downwards, if necessary, depending upon the clinical response and tolerability of the patient [see Clinical Studies (14.1, 14.2 and 14.3)].

Table 1: Recommended Dosing for SEROQUEL XR
Indication	Initial Dose and Titration	Recommended Dose	Maximum Dose
Schizophrenia - Adults	Day 1: 300 mg/day Dose increases can be made at intervals as short as 1 day and in increments of up to 300 mg/day	400-800 mg/day	800 mg/day
Schizophrenia - Adolescents (13 to 17 years)	Day 1: 50 mg/day Day 2: 100 mg/day Day 3: 200 mg/day Day 4: 300 mg/day Day 5: 400 mg/day	400-800 mg/day	800 mg/day
Schizophrenia Maintenance - Monotherapy - Adults	Not applicable	400-800 mg/day	800 mg/day
Bipolar I Disorder manic or mixed - Acute monotherapy or adjunct to lithium or divalproex - Adults	Day 1: 300 mg/day Day 2: 600 mg/day Day 3: between 400 and 800 mg/day	400-800 mg/day	800 mg/day
Bipolar I Disorder, manic - Acute monotherapy - Children and Adolescents (10 to 17 years)	Day 1: 50 mg/day Day 2: 100 mg/day Day 3: 200 mg/day Day 4: 300 mg/day Day 5: 400 mg/day	400-600 mg/day	600 mg/day
Bipolar Disorder, Depressive Episodes - Adults	Day 1: 50 mg/day Day 2: 100 mg/day Day 3: 200 mg/day Day 4: 300 mg/day	300 mg/day	300 mg/day
Bipolar I Disorder Maintenance - Adjunct to lithium or divalproex - Adults	Not applicable	400-800 mg/day	800 mg/day
Major Depressive Disorder - Adjunctive Therapy with Antidepressants - Adults	Day 1: 50 mg/day Day 2: 50 mg/day Day 3: 150 mg/day	150-300 mg/day	300 mg/day

Maintenance Treatment for Schizophrenia and Bipolar I Disorder

Maintenance Treatment—Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment [see Clinical Studies (14.1, 14.2)].

Dose Modifications in Elderly Patients

Consideration should be given to a slower rate of dose titration and a lower target dose in the elderly and in patients who are debilitated or who have a predisposition to hypotensive reactions [see Use in Specific Populations (8.5, 8.7), and Clinical Pharmacology (12.3)]. When indicated, dose escalation should be performed with caution in these patients.

Elderly patients should be started on SEROQUEL XR 50 mg/day and the dose can be increased in increments of 50 mg/day depending on the clinical response and tolerability of the individual patient.

Dose Modifications in Hepatically Impaired Patients

Patients with hepatic impairment should be started on SEROQUEL XR 50 mg/day. The dose can be increased daily in increments of 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient.

Dose Modifications when used with CYP3A4 Inhibitors

SEROQUEL XR dose should be reduced to one‑sixth of original dose when co-medicated with a potent CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc.). When the CYP3A4 inhibitor is discontinued, the dose of SEROQUEL XR should be increased by 6-fold [see Clinical Pharmacology (12.3) and Drug Interactions (7.1)].

Dose Modifications when used with CYP3A4 Inducers

SEROQUEL XR dose should be increased up to 5-fold of the original dose when used in combination with a chronic treatment (e.g., greater than 7-14 days) of a potent CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc.). The dose should be titrated based on the clinical response and tolerance of the individual patient. When the CYP3A4 inducer is discontinued, the dose of SEROQUEL XR should be reduced to the original level within 7-14 days [see Clinical Pharmacology (12.3) and Drug Interactions (7.1)].

Re-initiation of Treatment in Patients Previously Discontinued

Although there are no data to specifically address re-initiation of treatment, it is recommended that when restarting therapy of patients who have been off SEROQUEL XR for more than one-week, the initial dosing schedule should be followed. When restarting patients who have been off SEROQUEL XR for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated.

Switching Patients from SEROQUEL Tablets to SEROQUEL XR Tablets

Patients who are currently being treated with SEROQUEL (immediate release formulation) may be switched to SEROQUEL XR at the equivalent total daily dose taken once daily. Individual dosage adjustments may be necessary.

Switching from Antipsychotics

There are no systematically collected data to specifically address switching patients from other antipsychotics to SEROQUEL XR, or concerning concomitant administration with other antipsychotics. While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients, more gradual discontinuation may be most appropriate for others. In all cases, the period of overlapping antipsychotic administration should be minimized. When switching patients from depot antipsychotics, if medically appropriate, initiate SEROQUEL XR therapy in place of the next scheduled injection. The need for continuing existing extrapyramidal syndrome medication should be re-evaluated periodically.